Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

RTTNews | 1159 dias atrás
Stocktwits
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.

Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. Prior to that, he was Head of the Immunology, Hepatology & Dermatology Global Development Unit at Novartis.

He launched his career in the pharmaceutical industry in 2004, in early clinical research at Bristol Myers-Squibb Co. and then at Schering-Plough Research Institute.

Marcadores : TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | 517 dias atrás
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews | 655 dias atrás
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 664 dias atrás
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 762 dias atrás
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 846 dias atrás
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | 855 dias atrás
Swiss Shares Extend Losing Streak

Swiss Shares Extend Losing Streak

The Swiss stock market closed under pressure again on Tuesday, stretching its losing streak to three sessions while giving up more than 130 points or 1.1 percent in that span.
RTTNews | 4h 11min atrás
Ferramentas
Calendário Econômico
Horário do mercado
Taxas de juros
Calendário de feriados
Mercado Forex
Volatilidade no Forex
Correlação no Forex
Notícias sobre Forex
Análise de Forex
Dados do COT
Liquidez
Calculadoras Forex
Mapa do Calor do Forex
Mapa de calor de indicadores
Comunidade
Comunidade
Sistemas
Sistemas Mais Populares
Estratégias
Concursos
Gráficos de Forex
Sentimento do Forex
Indicador de Perspectivas
Análises
Corretoras
Empresas de trading proprietário
Serviços de VPS
Provedores de Sinais
Serviços de Programação de EA
Programas de afiliados
Serviços de Corretora PAMM
Serviços de Programa de Reembolso
Plataformas de Trading
Expert Advisors
Corretoras de Criptomoedas
Cursos de trading
Corretoras
Spreads de Forex
Cotações de Corretoras de Forex
Swaps de Corretoras de Forex
Volume da Corretora de Forex
Promoções de Corretoras de Forex
Comunicado De Imprensa
Plataforma
Widgets
Recursos
API
RSS
Stock Portfolio
Affiliate Software
Gráficos Avançados
Assistência
Perguntas Frequentes
Ajuda
Entre em contato conosco
Relatar um erro!
Sobre
Blog
© 2025 Myfxbook Ltd. Todos os Direitos Reservados.
AVISO DE ALTO RISCO: A negociação no mercado de câmbio traz consigo um alto nível de risco que pode não ser adequado para qualquer investidor. A alavancagem cria exposição adicional a riscos e perdas. Antes de decidir negociar no mercado de câmbio, considere cuidadosamente seus objetivos de investimento, seu nível de experiência e sua tolerância ao risco. Você pode perder parte de seu investimento inicial ou todo ele. Não invista um dinheiro que você não tem condições de perder. Informe-se sobre os riscos associados à negociação no mercado de câmbio e procure o conselho de um consultor financeiro ou fiscal independente, caso tenha alguma dúvida. Quaisquer dados e informações são fornecidos "como estão" exclusivamente para fins informativos. Eles não se destinam a fins comerciais ou de aconselhamento. O desempenho passado não é indicativo de resultados futuros.